These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Tumor necrosis factor-alpha monoclonal antibodies for Crohn's disease: tipping the balance. Danese S; Pagano N; Angelucci E; Stefanelli T; Repici A; Omodei P; Daperno M; Malesci A Curr Med Chem; 2007; 14(14):1489-97. PubMed ID: 17584058 [TBL] [Abstract][Full Text] [Related]
6. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease. Ricciardelli I; Lindley KJ; Londei M; Quaratino S Immunology; 2008 Oct; 125(2):178-83. PubMed ID: 18422560 [TBL] [Abstract][Full Text] [Related]
8. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611 [TBL] [Abstract][Full Text] [Related]
9. Transcending conventional therapies: the role of biologic and other novel therapies. Sandborn WJ Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043 [TBL] [Abstract][Full Text] [Related]
10. Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients With Crohn's Disease. Fang L; Pang Z; Shu W; Wu W; Sun M; Cong Y; Liu Z Inflamm Bowel Dis; 2018 Jul; 24(8):1733-1744. PubMed ID: 29718341 [TBL] [Abstract][Full Text] [Related]
11. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Di Sabatino A; Ciccocioppo R; Cinque B; Millimaggi D; Morera R; Ricevuti L; Cifone MG; Corazza GR Gut; 2004 Jan; 53(1):70-7. PubMed ID: 14684579 [TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn's disease. Shetty A; Forbes A Am J Pharmacogenomics; 2002; 2(4):215-21. PubMed ID: 12421092 [TBL] [Abstract][Full Text] [Related]
14. Selective immunomodulation in patients with inflammatory bowel disease--future therapy or reality? van Hogezand RA; Verspaget HW Neth J Med; 1996 Feb; 48(2):64-7. PubMed ID: 8819802 [TBL] [Abstract][Full Text] [Related]
15. Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease. Mouser JF; Hyams JS Clin Ther; 1999 Jun; 21(6):932-42; discussion 931. PubMed ID: 10440618 [TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Behm BW; Bickston SJ Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120 [TBL] [Abstract][Full Text] [Related]